← TENET HEALTHCARE CORP

Annual Trend FY 2016 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025
Cash flows from operating activities:
Adjustments to reconcile net income to net cash provided by operating activities:
Net Income (Loss) Available to Common Stockholders, Basic ($192.0m) ($704.0m) $111.0m ($232.0m) $399.0m $914.0m $411.0m $611.0m $3.2b $1.4b
Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent ($187.0m) ($704.0m) $108.0m ($243.0m) $399.0m $915.0m $410.0m $611.0m $3.2b $1.4b
Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest $181.0m ($320.0m) $463.0m $143.0m $768.0m $1.5b $1.0b $1.3b — —
Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent ($5.0m) $0 $3.0m $11.0m $0 ($1.0m) $1.0m $0 — —
Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest ($5.0m) $0 $3.0m $11.0m $0 ($1.0m) $1.0m $0 — —
Net Income (Loss) Attributable to Noncontrolling Interest $368.0m $384.0m $355.0m $386.0m $369.0m $562.0m $590.0m $700.0m $864.0m $960.0m
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest $176.0m ($320.0m) $466.0m $154.0m $768.0m $1.5b $1.0b $1.3b $4.1b $2.4b
Amortization of Debt Issuance Costs and Discounts $41.0m $44.0m $45.0m $35.0m $38.0m $33.0m $33.0m $32.0m $26.0m $23.0m
Amortization of Intangible Assets — $172.0m $185.0m $188.0m $172.0m $188.0m $172.0m $174.0m $172.0m $166.0m
Amortization of debt discount and debt issuance costs $41.0m $44.0m $45.0m $35.0m $38.0m $33.0m $33.0m $32.0m $26.0m $23.0m
Depreciation $850.0m $870.0m $802.0m $850.0m $857.0m $855.0m $669.0m $696.0m $646.0m $697.0m
Depreciation, Depletion and Amortization $850.0m $870.0m $802.0m $850.0m $857.0m $855.0m $841.0m $870.0m $818.0m $863.0m
Deferred Income Tax Expense (Benefit) $41.0m $200.0m $150.0m $137.0m ($128.0m) $250.0m $209.0m $52.0m ($103.0m) $9.0m
Deferred Other Tax Expense (Benefit) $41.0m $200.0m $149.0m $133.0m ($127.0m) $250.0m $209.0m $52.0m ($103.0m) $9.0m
Equity Method Investment, Other than Temporary Impairment — $31.0m — — — — — — — —
Impairment and restructuring charges, and acquisition-related costs $202.0m $541.0m $209.0m $185.0m $290.0m $85.0m $226.0m $137.0m $102.0m $130.0m
Payment, Tax Withholding, Share-based Payment Arrangement — — — — — — — — — $51.0m
Share-based Payment Arrangement, Expense — — $46.0m $42.0m $44.0m $56.0m $56.0m $66.0m $67.0m $104.0m
Share-based Payment Arrangement, Noncash Expense $68.0m $59.0m $46.0m $42.0m $44.0m $56.0m $56.0m $66.0m $67.0m $104.0m
Gain (Loss) on Disposition of Assets — — — — — — $117.0m $29.0m $4.0m $4.0m
Gain (Loss) on Extinguishment of Debt — ($164.0m) $1.0m ($227.0m) ($316.0m) ($74.0m) ($109.0m) ($11.0m) ($8.0m) ($4.0m)
Income (Loss) from Equity Method Investments $131.0m $144.0m $150.0m $175.0m $169.0m $218.0m $216.0m $228.0m $260.0m $264.0m
Income Tax Expense (Benefit) $67.0m $219.0m $176.0m $153.0m ($97.0m) $411.0m $344.0m $306.0m $1.2b $433.0m
Interest Expense Nonoperating — — — — — — — — $826.0m $821.0m
Loss from early extinguishment of debt $30.0m $164.0m ($1.0m) $227.0m $316.0m $74.0m $109.0m $11.0m $8.0m $4.0m
Other Nonoperating Income (Expense) — — — — $1.0m $14.0m $10.0m $19.0m $126.0m $117.0m
Income (Loss) from Equity Method Investments, Net of Dividends or Distributions — $18 $12 $32 $37 $10 ($2) $13 $29 $34
Changes in operating assets and liabilities:
Additional Financial Items
Accounts payable, accrued expenses and other current liabilities ($51.0m) ($10.0m) ($152.0m) $36.0m $1.3b ($584.0m) ($898.0m) $215.0m ($30.0m) $209.0m
Accounts receivable ($1.6b) ($1.4b) ($134.0m) ($247.0m) $195.0m ($197.0m) ($140.0m) ($29.0m) $245.0m $20.0m
Advances from managed care payers — — — — — — $0 $0 $342.0m $0
Equity in earnings of unconsolidated affiliates, net of distributions received ($13.0m) ($18.0m) ($12.0m) ($32.0m) ($37.0m) ($10.0m) $2.0m ($13.0m) ($29.0m) ($34.0m)
Gain (Loss) Related to Litigation Settlement ($293.0m) ($23.0m) ($38.0m) ($141.0m) ($44.0m) ($116.0m) ($70.0m) ($47.0m) ($35.0m) ($64.0m)
Gain (Loss) on Investments $8.0m — — — — — — — — —
Goodwill $7.4b $7.0b $7.3b $7.3b $8.8b $9.3b $10.1b $10.3b $10.7b $11.2b
Income tax payments, net ($33.0m) ($56.0m) ($25.0m) ($12.0m) ($12.0m) ($92.0m) ($161.0m) ($243.0m) ($1.3b) ($450.0m)
Income taxes ($8.0m) ($38.0m) ($3.0m) $8.0m $19.0m $68.0m ($26.0m) $10.0m $16.0m ($25.0m)
Increase (Decrease) in Accounts Receivable $1.6b $1.4b $134.0m $247.0m ($195.0m) $197.0m $140.0m $29.0m ($245.0m) ($20.0m)
Inventories and other current assets ($83.0m) ($35.0m) $17.0m ($94.0m) ($145.0m) ($52.0m) ($64.0m) ($139.0m) ($86.0m) ($73.0m)
Litigation and investigation costs $293.0m $23.0m $38.0m $141.0m $44.0m $116.0m $70.0m $47.0m $35.0m $64.0m
Net losses (gains) on sales, consolidation and deconsolidation of facilities — ($144.0m) ($127.0m) $15.0m ($14.0m) ($445.0m) — ($23.0m) ($2.9b) $1.0m
Other items, net $16.0m $29.0m $54.0m $4.0m $10.0m ($64.0m) ($46.0m) $71.0m $33.0m $55.0m
Other long-term liabilities $40.0m $26.0m ($102.0m) $3.0m $221.0m $28.0m ($15.0m) $14.0m ($9.0m) $9.0m
Payments for restructuring charges, acquisition-related costs, and litigation costs and settlements ($691.0m) ($125.0m) ($163.0m) ($192.0m) ($333.0m) ($153.0m) ($214.0m) ($154.0m) ($153.0m) ($121.0m)
Proceeds from Contributions from Affiliates — — — — $187.0m — — — — —
Proceeds from Stock Options Exercised $4.0m — — — — — — — — —
Proceeds from borrowings — — — — — $2.9b $2.0b $1.4b $23.0m $2.3b
Proceeds from sales of facilities and other assets $573.0m $827.0m $543.0m $63.0m $77.0m $1.2b $210.0m $71.0m $5.0b $38.0m
Repayments of advances from managed care payers — — — — — — $0 $0 ($310.0m) ($32.0m)
Repayments of borrowings — — — — — ($3.2b) ($2.9b) ($1.5b) ($2.2b) ($2.4b)
Restructuring Costs — $117.0m $115.0m $137.0m $184.0m $57.0m $118.0m $79.0m $56.0m $44.0m
Stock-based compensation expense $68.0m $59.0m $46.0m $42.0m $44.0m $56.0m $56.0m $66.0m $67.0m $104.0m
Unrealized Gain (Loss) on Investments — — — — — — $1.0m — — —
Net Cash Provided by (Used in) Operating Activities $558.0m $1.2b $1.0b $1.2b $3.4b $1.6b $1.1b $2.4b $2.0b $3.5b
Cash flows from investing activities:
Payments to Acquire Property, Plant, and Equipment $875.0m $707.0m $617.0m $670.0m $540.0m $658.0m $762.0m $751.0m $931.0m $1.0b
Payments to Acquire Businesses, Net of Cash Acquired $117.0m $50.0m $113.0m $25.0m $1.2b $1.2b $234.0m $224.0m $571.0m $308.0m
Purchases of businesses or joint venture interests, net of cash acquired ($117.0m) ($50.0m) ($113.0m) ($25.0m) ($1.2b) ($1.2b) ($234.0m) ($224.0m) ($571.0m) ($308.0m)
Payments to Acquire Investments — — — $62.0m $44.0m $108.0m $92.0m $104.0m $94.0m $90.0m
Purchases of marketable securities and long-term investments — ($81.0m) ($148.0m) ($62.0m) ($44.0m) ($108.0m) ($92.0m) ($104.0m) ($94.0m) ($90.0m)
Net gains from the sale of investments and long-lived assets — — — — ($25.0m) ($23.0m) ($117.0m) ($29.0m) ($4.0m) ($4.0m)
Proceeds from sales of marketable securities and long-term investments $62.0m $36.0m $199.0m $82.0m $59.0m $31.0m $76.0m $50.0m $63.0m $93.0m
Payments for (Proceeds from) Other Investing Activities $3.0m $7.0m $15.0m $0 ($18.0m) $7.0m $6.0m $11.0m $19.0m ($2.0m)
Net Cash Provided by (Used in) Investing Activities ($430.0m) $21.0m ($115.0m) ($619.0m) ($1.6b) ($714.0m) ($808.0m) ($969.0m) $3.4b ($1.3b)
Cash flows from financing activities:
Debt issuance costs ($12.0m) ($62.0m) $0 ($70.0m) ($48.0m) ($31.0m) ($24.0m) ($16.0m) $0 ($32.0m)
Payments for Repurchase of Common Stock — $0 — — — — $250.0m $200.0m $672.0m $1.4b
Repurchases of common stock $0 $0 — — $0 $0 ($250.0m) ($200.0m) ($672.0m) ($1.4b)
Proceeds from the sale of noncontrolling interests $22.0m $31.0m $20.0m $21.0m $14.0m $25.0m $27.0m $43.0m $23.0m $42.0m
Purchases of noncontrolling interests ($186.0m) ($729.0m) ($647.0m) ($11.0m) ($39.0m) ($27.0m) ($100.0m) ($167.0m) ($200.0m) ($92.0m)
Proceeds from (Payments for) Other Financing Activities $16.0m $29.0m $54.0m $4.0m $10.0m ($64.0m) ($46.0m) $71.0m $33.0m $55.0m
Net Cash Provided by (Used in) Financing Activities $232.0m ($1.3b) ($1.1b) ($763.0m) $385.0m ($936.0m) ($1.8b) ($1.0b) ($3.7b) ($2.4b)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect — — — ($149.0m) $2.2b ($82.0m) ($1.5b) $370.0m $1.8b ($136.0m)
Net increase (decrease) in cash and cash equivalents $360.0m ($105.0m) ($200.0m) ($149.0m) $2.2b ($82.0m) ($1.5b) $370.0m $1.8b ($136.0m)
Cash and cash equivalents at beginning of period $356.0m $716.0m $611.0m $262.0m $2.4b $2.4b $858.0m $1.2b $3.0b $2.9b
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents — — — $262.0m $2.4b $2.4b $858.0m $1.2b $3.0b $2.9b
Supplemental disclosure of cash flow information:
Interest Paid, Excluding Capitalized Interest, Operating Activities $932.0m $939.0m $976.0m $946.0m $962.0m $937.0m $848.0m $882.0m $851.0m $865.0m
Income Taxes Paid, Net $33.0m $56.0m $25.0m $12.0m $12.0m $92.0m $161.0m $243.0m $1.3b $450.0m

Data sourced from SEC EDGAR 10-K filings via EdgarTools. Amounts are shown in USD as reported in each fiscal year filing.

Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.